CE

CELLUMED CO., LTD.

Develops bone grafts, artificial joints, and enzymes for the biopharmaceutical sector.

049180 | KO

Overview

Corporate Details

ISIN(s):
KR7049180003
LEI:
Country:
South Korea
Address:
서울특별시 금천구 디지털로 130 402(가산동, 에이스테크노타워 9차), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CELLUMED CO., LTD. is a biotechnology company specializing in the development and manufacturing of medical devices and biologics. A pioneer in tissue banking, the company provides a range of bone graft materials, including allografts and xenografts, supported by advanced tissue processing technologies. Its product portfolio also includes musculoskeletal medical devices, such as artificial knee joints. Additionally, Cellumed supplies high-quality enzymes essential for the production of RNA-based medicines and vaccines, catering to the biopharmaceutical sector.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-19 00:00
Share Issue/Capital Change
기타주요경영사항 (제3자배정 유상증자 소액공모 철회의 건)
Korean 6.5 KB
2025-09-19 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 31.4 KB
2025-09-19 00:00
Share Issue/Capital Change
[기재정정]소액공모공시서류(지분증권)
Korean 1.9 MB
2025-09-19 00:00
Share Issue/Capital Change
소액공모실적보고서
Korean 26.0 KB
2025-08-26 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 109.8 KB
2025-08-25 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (채권압류 및 전부명령 항고 취하의 건)
Korean 8.2 KB
2025-08-25 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 72.5 KB
2025-08-18 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (집행판결 청구소송 합의의 건)
Korean 13.8 KB
2025-08-14 00:00
Audit Report / Information
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 12.2 KB
2025-08-14 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 1.9 MB
2025-07-28 00:00
Legal Proceedings Report
소송등의판결ㆍ결정(일정금액이상의청구) (특허권 압류명령)
Korean 12.3 KB
2025-07-25 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (채권압류 및 전부명령 판결에 대한 항고의 건)
Korean 10.0 KB
2025-07-11 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (주식압류명령의 판결에 대한 항고의 건)
Korean 9.3 KB
2025-06-13 00:00
Legal Proceedings Report
소송등의판결ㆍ결정(일정금액이상의청구) (채권압류 및 전부명령)
Korean 12.5 KB
2025-06-13 00:00
Legal Proceedings Report
소송등의판결ㆍ결정(일정금액이상의청구) (주식압류명령)
Korean 14.2 KB

Automate Your Workflow. Get a real-time feed of all CELLUMED CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CELLUMED CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CELLUMED CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Xbrane Biopharma Logo
Develops affordable biosimilars for serious diseases using patented, high-yield production tech.
Sweden
XBRANE
Xcell Therapeutics Inc. Logo
Develops serum-free media & automated systems for cell therapy & regenerative medicine.
South Korea
373110
Xencor Inc Logo
Engineering antibody & cytokine therapeutics for cancer and autoimmune diseases via its XmAb platform.
United States of America
XNCR
Xenetic Biosciences, Inc. Logo
Advancing DNase & CAR T immune-oncology platforms to treat hard-to-treat cancers.
United States of America
XBIO
Xenon Pharmaceuticals Inc. Logo
A neuroscience biopharma developing novel therapeutics for epilepsy and depression.
United States of America
XENE
Xeris Biopharma Holdings, Inc. Logo
Develops ready-to-use injectable drugs for chronic, metabolic, and rare diseases.
United States of America
XERS
XORTX Therapeutics Inc. Logo
Developing late-stage, uric acid-lowering therapies for gout and progressive kidney disease.
United States of America
XRTX
Xspray Pharma Logo
Develops improved cancer drugs (PKIs) using patented tech to circumvent secondary patents.
Sweden
XSPRAY
XTL Biopharmaceuticals Ltd. Logo
Acquires and develops late-stage drugs for unmet medical needs, focusing on autoimmune diseases.
Israel
XTLB

Talk to a Data Expert

Have a question? We'll get back to you promptly.